Infection-Associated Cancer Risks and Tumor Mutational Burden in Immunocompromised Individuals: A Systematic Review and Meta-Analysis - Summary - MDSpire
Advertisement
Infection-Associated Cancer Risks and Tumor Mutational Burden in Immunocompromised Individuals: A Systematic Review and Meta-Analysis
To assess the risks of infection-associated malignancies, particularly focusing on specific types of cancers, in immunocompromised populations and explore the correlation with tumor mutational burden (TMB).
Key Findings:
Immunocompromised populations have a distinct cancer profile with high-risk cancers linked to infections, such as lymphomas and skin cancers.
Tumor mutational burden (TMB) serves as a potential biomarker for immunogenicity and cancer treatment response.
Higher TMB is associated with improved overall survival in immune checkpoint inhibitor treatments.
Interpretation:
Impaired immune surveillance in immunocompromised individuals may allow high-TMB cancers to thrive, suggesting a need for targeted prevention and treatment strategies, particularly in clinical settings.
Limitations:
Current reviews inadequately address infection-related cancer risks in immunocompromised patients, particularly in longitudinal studies.
Lack of comprehensive studies summarizing cancer burden in these populations, especially in diverse geographic regions.
Conclusion:
This study highlights the urgent need for further exploration of infection-associated cancer risks and TMB in immunocompromised individuals to inform treatment strategies.
One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.
